Bispecific Antibody Market 2023 to 2033: Advanced R&D Process StrategiesPosted by Ganesh Shinde on February 23rd, 2023  The global bispecific antibody market is expected to reach 0 million by the end of 2023, and billion by 2033, representing a 7.2% CAGR. The bispecific antibody business has benefited greatly from antibody engineering. Much progress has been achieved in generating innovative antibody formats and engineering procedures that allow the creation of bispecific antibodies with improved efficacy and stability in recent years. Advances in recombinant DNA technology and protein engineering, for example, have permitted the development of bispecific antibodies with enhanced pharmacokinetics, lower immunogenicity, and higher tumour penetration. The rising prevalence of cancer and autoimmune illnesses is also driving the bispecific antibody market. These disorders continue to be a large unmet medical need, and developing novel and effective therapeutics is critical for improving patient outcomes. Bispecific antibodies show promise in the treatment of cancer and autoimmune illnesses because they can target two distinct antigens at the same time, increasing therapeutic efficacy. For example, blinatumomab, a bispecific antibody targeting CD19 and CD3, has been licenced for the treatment of B-cell acute lymphoblastic leukaemia (ALL) and is being tested for other hematologic cancers. Bispecific Antibody Market: Segmentation By Drug Type:
By Indication:
By Distribution Channel:
Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables. Read More@ https://www.futuremarketinsights.com/reports/bispecific-antibody-market Competitive Analysis By Prominent Market Players
Like it? Share it! More by this author |